Mapi Pharma Ltd.
Records under this name other than the patents Mapi Pharma Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 22 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,413,311 | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,161,688 | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,829,208 | Process for the Preparation of Darunavir and Darunavir Intermediates Lapsed on the fee record Ended Sep 9, 2026 · High confidence | Lapsed on the fee record | Ended Sep 9, 2026 | High confidence |
| US 8,772,503 | Processes for the Preparation of Deferasirox, and Deferasirox Polymorphs Lapsed on the fee record Ended Jul 8, 2026 · High confidence | Lapsed on the fee record | Ended Jul 8, 2026 | High confidence |
| US 9,994,522 | Amorphous form of apremilast Lapsed on the fee record Ended Jun 12, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2026 | From the USPTO record |
| US 8,735,627 | Intermediate compounds and process for the preparation of fingolimod Lapsed on the fee record Ended May 27, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 27, 2026 | From the USPTO record |
| US 9,617,241 | Intermediate compounds and process for the preparation of efinaconazole Lapsed on the fee record Ended Apr 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | From the USPTO record |
| US 8,410,176 | Intermediate compounds and processes for the preparation of tapentadol and related compounds Lapsed on the fee record Ended Apr 2, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 2, 2025 | From the USPTO record |
| US 9,453,024 | Polymorphs of darunavir Lapsed on the fee record Ended Sep 27, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 27, 2024 | From the USPTO record |
| US 8,865,742 | Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium Lapsed on the fee record Ended Oct 21, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 21, 2022 | From the USPTO record |